NASDAQ:EFTR

Effector Therapeutics Stock Forecast

etoro logo Buy EFTR
*Your capital is at risk
$0.0006
+0 (+0%)
At Close: Jun 03, 2026
Add EFTR to Watchlist?
Some Reasons Why To Add EFTR:
  • +200.0% price growth over the last year
  • Strong return on equity of 3,771.6%
  • +200.0% YTD performance

EFTR Performance

FAQ

What is the symbol for eFFECTOR Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for eFFECTOR Therapeutics, Inc. is EFTR and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell eFFECTOR Therapeutics, Inc. Stock?
eFFECTOR Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy eFFECTOR Therapeutics, Inc. Stock?
eFFECTOR Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy eFFECTOR Therapeutics, Inc. Stock.

What's the current price of eFFECTOR Therapeutics, Inc. Stock?
As of the end of day on the Jun 03, 2026, the price of an eFFECTOR Therapeutics, Inc. (EFTR) share was $0.0006.

What is the 52-week high and low for eFFECTOR Therapeutics, Inc. Stock?
The 52-week high for eFFECTOR Therapeutics, Inc. Stock is $1.50 and the 52-week low is $0.0002.

What is the market capitalization of eFFECTOR Therapeutics, Inc. Stock?
As of the Jun 03, 2026, the market capitalization of eFFECTOR Therapeutics, Inc. is 2.823K.

When is the next earnings date for eFFECTOR Therapeutics, Inc.?
The upcoming earnings date for eFFECTOR Therapeutics, Inc. is Aug 12, 2026.
Click to get the best stock tips daily for free!
ABOUT EFFECTOR THERAPEUTICS, INC.
eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE